Lucas Rodriguez

CerSci

Dallas-based Biotech CerSci Acquired by ACADIA Pharmaceutical in $52.5M Deal

by | Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
MORE
CerSci
Meet the Innovators: Lucas Rodriguez, CEO of CerSci Therapeutics
by | Apr 1, 2019
CerSci's focus is on alleviating human suffering and rescuing society from the ongoing opioid crisis via a pain drug that does not affect the central nervous system.
MORE
Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.